Xcorporeal Stock

Xcorporeal EPS

The Earnings per Share (EPS) of Xcorporeal (XCRP) as of Aug 4, 2026 is -1.57 USD.

EPS

-1.57USD

Last updated:

Earnings per Share (EPS) of Xcorporeal is 2026 -1.57 USD. Earnings per Share (EPS) of Xcorporeal was 2025 - USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

Xcorporeal Stock analysis

What does Xcorporeal do? Xcorporeal Inc is an American medical technology company specialized in the development and marketing of innovative medical devices. The company was founded in 2002 and is headquartered in Los Angeles, California. The company operates in the field of extracorporeal therapy, where blood is cleansed outside the body. The goal is to rid the body of toxins and excess fluids when the kidneys or liver are not functioning properly. Xcorporeal Inc's business model is based on the development and marketing of extracorporeal therapy devices. The company aims to lead in the field of renal replacement therapy, blood purification, and soluble sepsis treatment. In this context, Xcorporeal Inc is a pioneer in the field of portable hemodialysis devices, which allow patients to receive continuous kidney function treatment. The devices are designed to be easy to use and provide patients with mobility and quality of life. Xcorporeal Inc offers a variety of products tailored to the needs of patients and medical personnel. The portable hemodialysis device FloWatch is one of Xcorporeal Inc's most well-known products. It allows patients to perform treatment at home, providing them with more flexibility and self-determination. Additionally, Xcorporeal Inc has also developed a solution for the treatment of sepsis. Soluble Sepsis Therapy (SST) is a groundbreaking procedure in which blood is pumped through a special filter technology to remove dangerous toxins and inflammatory substances from the blood. Xcorporeal Inc currently operates two divisions focused on other applications of extracorporeal therapy. The first division focuses on the development of devices for blood purification and fighting infections. The second division is involved in the development of medical instruments for use in research and development. Overall, Xcorporeal Inc has the potential to change the face of extracorporeal therapy. With its innovative products and pioneering spirit in the field of portable hemodialysis devices, the company has shown that it is capable of transforming the market and revolutionizing the way extracorporeal therapy is practiced. Xcorporeal is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Xcorporeal stock

Earnings per Share (EPS) of Xcorporeal is -1.57 USD in 2026.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Xcorporeal since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

Income Statement — Xcorporeal

All Key Metrics — Xcorporeal